Abstract
Cancer cells apply the Warburg pathway to meet their increased metabolic demands caused by their rapid growth and proliferation and also creates an acidic environment to promote cancer cell invasion. 3-bromopyruvate (3-BrP) as an anti-cancer agent disrupts glycolytic pathway. Moreover, one of the mechanism of actions of Methyl Jasmonate (MJ) is interference in glycolysis. Hence, the aim of this study was to evaluate MJ and 3-BrP interaction. MTT assay was used to determine IC50 and synergistic concentrations. Combination index was applied to evaluate the drug- drug interaction. Human tumor xenograft breast cancer mice was used to evaluate drug efficacy in vivo. Tumor size was considered as a drug efficacy criterion. In addition to drug efficacy, probable side effects of these drugs including hepatotoxicity, renal failure, immunotoxicity, and losing weight were evaluated. Serum alanine aminotransferase and aspartate aminotransferase for hepatotoxicity, serum urea and creatinine level for the possibility of renal failure and changes in body weight were measured to evaluate drug toxicity. IL10 and TGFβ secretion in supernatant of isolated splenocytes from treated mice were assessed to check immunotoxicity. 3-BrP synergistically augmented the efficacy of MJ in the specific concentrations. This polytherapy was more effective than monotherapy of 3-BrP, MJ, and also surprisingly cyclophosphamide as a routine treatment for breast cancer in the tumor bearing mice. These results have been shown by decrease in tumor volume and increase of tumor growth inhibition percentage. This combination therapy didn’t have any noticeable side effects on kidney, liver, and immune system and body weight.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahlmann M, Hempel G (2016) The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 78:661–671. https://doi.org/10.1007/s00280-016-3152-1
Almstedt HC, Grote S, Perez SE et al (2017) Training-related improvements in musculoskeletal health and balance: a 13-week pilot study of female cancer survivors. Eur J Cancer Care (Engl) 26:3909–3913. https://doi.org/10.1111/ecc.12442
Anderson M, Marayati R, Moffitt R, Jen Yeh J (2017) Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 8:56081. https://doi.org/10.18632/oncotarget.9760
Attia YM, EL-Abhar HS, Al Marzabanil MM et al (2015) Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines. BMC Cancer 15:838. https://doi.org/10.1186/s12885-015-1850-4
Bhardwaj V, Rizvi N, Lai MB et al (2010) Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. Anticancer Res 30:743–749
Bohloli M, Atashi A, Soleimani M et al (2016) Investigating effects of acidic pH on proliferation, invasion and drug-induced apoptosis in lymphoblastic leukemia. Cancer Microenviron 9:119–126. https://doi.org/10.1007/s12307-016-0187-0
Brand KA, Hermfisse U (1997) Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J 11:388–395. https://doi.org/10.1096/fasebj.11.5.9141507
Chen Y, Wei L, Zhang X et al (2018) 3-Bromopyruvate sensitizes human breast cancer cells to TRAIL-induced apoptosis via the phosphorylated AMPK-mediated upregulation of DR5. Oncol Rep 40:2435–2444. https://doi.org/10.3892/or.2018.6644
Creelman RA, Mullet JE (1997) Biosynthesis and action of Jasmonates in plants. Annu Rev Plant Physiol Plant Mol Biol 48:355–381. https://doi.org/10.1146/annurev.arplant.48.1.355
Dang CV (2011) Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol 76:369–374. https://doi.org/10.1101/sqb.2011.76.011296
Davies PJ (2010) The plant hormones: Their nature, occurrence, and functions. In: Plant Hormones: Biosynthesis, Signal Transduction, Action! Springer, pp 1–15
Dell’Antone P (2006) Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. Life Sci 79:2049–2055. https://doi.org/10.1016/j.lfs.2006.06.043
Dell’Antone P (2009) Targets of 3-Bromopyruvate, a new, energy depleting, anticancer agent. Med Chem (Los Angeles) 5:491–496. https://doi.org/10.2174/157340609790170551
El Sayed SM, Abou El-Magd RM, Shishido Y et al (2012) D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate. Cancer Gene Ther 19:1–18. https://doi.org/10.1038/cgt.2011.59
Fingrut O, Flescher E (2002) Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 16:608–616. https://doi.org/10.1038/sj.leu.2402419
Flescher E (2005) Jasmonates–a new family of anti-cancer agents. Anti-Cancer Drugs 16:911–916. https://doi.org/10.1097/01.cad.0000176501.63680.80
Flescher E (2007) Jasmonates in cancer therapy. Cancer Lett 245:1–10. https://doi.org/10.1016/j.canlet.2006.03.001
Ganapathy-Kanniappan S, Vali M, Kunjithapatham R et al (2010) 3-Bromopyruvate: a new targeted Antiglycolytic agent and a promise for Cancer therapy. Curr Pharm Biotechnol 999:1–13. https://doi.org/10.1006/jssc.2000.8803
Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS et al (2012) Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using Glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology 262:834–845. https://doi.org/10.1148/radiol.11111569
Geschwind JF, Georgiades CS, Ko YH, Pedersen PL (2004) Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 4:449–457. https://doi.org/10.1586/14737140.4.3.449
Gold D, Pankova-Kholmyansky I, Fingrut O, Flescher E (2003) The antiparasitic actions of plant jasmonates. J Parasitol 89:1242–1244. https://doi.org/10.1645/GE-94R
Grigorian A, O'Brien CB (2014) Hepatotoxicity secondary to chemotherapy. J Clin Transl Hepatol 2:95–102. https://doi.org/10.14218/JCTH.2014.00011
Gwaltney-Brant S (2014) Immunotoxicity biomarkers. Biomarkers in Toxicology 2014:373–385. https://doi.org/10.1016/B978-0-12-404630-6.00022-1
Hamanaka RB, Chandel NS (2012) Targeting glucose metabolism for cancer therapy: figure 1. J Exp Med 209:211–215. https://doi.org/10.1084/jem.20120162
Hashem FM, Nasr M, Khairy A (2008) In-vivo anti-tumor effect of 5-fluorouracil loaded chitosansodium deoxycholate nanoparticles. J Appl Toxicol 28:156–163. https://doi.org/10.1002/jat.1261
Heyfets A, Flescher E (2007) Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-d-glucose. Cancer Lett 250:300–310. https://doi.org/10.1016/j.canlet.2006.10.013
Hulleman E, Kazemier KM, Holleman A et al (2009) Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113:2014–2021. https://doi.org/10.1182/blood-2008-05-157842
Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83–91. https://doi.org/10.1016/S0304-3835(01)00667-X
Ko YH, Smith BL, Wang Y et al (2004) Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269–275. https://doi.org/10.1016/j.bbrc.2004.09.047
Kosoko AM, Molokwu CJ, Farombi EO, Ademowo OG (2012) The protective effects of methyl jasmonate against adriamycin--induced hepatic and renal toxicities. Afr J Med Med Sci 41(Suppl):117–124
Langroudi L, Hassan ZM, Ebtekar M et al (2010) A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. Int Immunopharmacol 10:1055–1061. https://doi.org/10.1016/j.intimp.2010.06.005
Li J, Chen K, Wang F et al (2017) Methyl jasmonate leads to necrosis and apoptosis in hepatocellular carcinoma cells via inhibition of glycolysis and represses tumor growth in mice. Oncotarget 8:45965–45980. https://doi.org/10.18632/oncotarget.17469
Man S, Bocci G, Francia G et al (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731–2735
Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG et al (2017) Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 14:11–31. https://doi.org/10.1038/nrclinonc.2016.60
Massagué J (2008) TGFβ in Cancer. Cell 134:215–230. https://doi.org/10.1016/j.cell.2008.07.001
Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: Cancer’s stygian link to the “Warburg effect” and a pivotal target for effective therapy. Semin Cancer Biol 19:17–24. https://doi.org/10.1016/j.semcancer.2008.11.006
Merriwether EN, Hastings MK, Bohnert KL et al (2017) Impact of foot progression angle modification on plantar loading in individuals with diabetes mellitus and peripheral neuropathy. Edorium J Disabil Rehabil 10:4173–4183. https://doi.org/10.1021/acsnano.5b07425.Molecular
Oboh G, Ogunruku OO (2010) Cyclophosphamide-induced oxidative stress in brain: protective effect of hot short pepper (Capsicum frutescens L. var. abbreviatum). Exp Toxicol Pathol 62:227–233. https://doi.org/10.1016/j.etp.2009.03.011
Okano T, Saegusa J, Nishimura K et al (2017) 3-bromopyruvate ameliorate autoimmune arthritis by modulating Th17/Treg cell differentiation and suppressing dendritic cell activation. Sci Rep 7:42412. https://doi.org/10.1038/srep42412
Pazhayattil GS, Shirali AC (2014) Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis 7:457–468. https://doi.org/10.2147/IJNRD.S39747
Pereira Da Silva AP, El-Bacha T, Kyaw N et al (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate 1. Biochem J 417:717–726. https://doi.org/10.1042/BJ20080805
Rotem R, Heyfets A, Fingrut O et al (2005) Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 65:1984–1993. https://doi.org/10.1158/0008-5472.CAN-04-3091
Schmitt S, Zischka H (2018) Targeting mitochondria for Cancer therapy. Dtsch Zeitschrift fur Onkol 50:124–130. https://doi.org/10.1055/a-0657-4437
Sembdner G, Parthier B (1993) The Biochemis try and the physiological and molecular actions of Jasmonates. Annu Rev Plant Physiol Plant Mol Bioi 44:569–589. https://doi.org/10.1146/annurev.arplant.48.1.355
Spitz DR, Sim JE, Ridnour LA et al (2006) Glucose deprivation-induced oxidative stress in human tumor cells: a fundamental defect in metabolism? Ann N Y Acad Sci 899:349–362. https://doi.org/10.1111/j.1749-6632.2000.tb06199.x
Starzl TE, Penn I, Schroter G et al (1971) Cyclophosphamide and human organ transplantation. Lancet 2:70. https://doi.org/10.1016/S0140-6736(71)92046-0
Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10:671–684. https://doi.org/10.1038/nrd3504
Wasternack C (2007) Jasmonates: an update on biosynthesis, signal transduction and action in plant stress093/ response, growth and development. Ann Bot 100(4):681–697.
Wu W, Zhao S (2013) Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin Shanghai 45:18–26. https://doi.org/10.1093/abbs/gms104
Wu L, Xu J, Yuan W et al (2014) The reversal effects of 3-Bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cells. PLoS One. https://doi.org/10.1371/journal.pone.0112132.g001
Yadav S, Pandey SK, Goel Y et al (2018) Protective and recuperative effects of 3-bromopyruvate on immunological, hepatic and renal homeostasis in a murine host bearing ascitic lymphoma: implication of niche dependent differential roles of macrophages. Biomed Pharmacother 99:970–985. https://doi.org/10.1016/j.biopha.2018.01.149
Yehia R, Hathout RM, Attia DA et al (2017) Anti-tumor efficacy of an integrated methyl dihydrojasmonate transdermal microemulsion system targeting breast cancer cells: in vitro and in vivo studies. Colloids Surfaces B Biointerfaces 155:512–521. https://doi.org/10.1016/j.colsurfb.2017.04.031
Zhang X, Varin E, Briand M et al (2009) Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-bromopyruvate on nude mice. Anticancer Res 29:1443–1448
Zhao L, Au JL, Wientjes MG (2010) Comparison of methods for evaluating drug-drug interaction. Front Biosci 2:241–249
Acknowledgements
We thank Heather Campbell (Roswell Park Comprehensive Cancer Institute, Department of Immunology, Buffalo, NY, USA) for editing manuscript regarding English grammar.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest declared.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yousefi, S., Darvishi, P., Yousefi, Z. et al. Effect of methyl jasmonate and 3-bromopyruvate combination therapy on mice bearing the 4 T1 breast cancer cell line. J Bioenerg Biomembr 52, 103–111 (2020). https://doi.org/10.1007/s10863-019-09811-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-019-09811-w